Skip to main content

Wall Street hikes forecasts for anti-obesity drug sales to $100 billion and beyond — A look at the numbers

Citi notched its estimate for incretin drug sales to $71 billion by 2035, up from its prior estimate of $55 billion. That view seems conservative. Here's why.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.